Origin and prognostic value of circulating KRAS mutations in lung cancer patients

Gautschi, O; Huegli, B; Ziegler, A; Gugger, M; Heighway, J; Ratschiller, D; Mack, P C; Gumerlock, P H; Kung, H J; Stahel, R A; Gandara, D R; Betticher, D C (2007). Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer letters, 254(2), pp. 265-73. Amsterdam: Elsevier 10.1016/j.canlet.2007.03.008

Full text not available from this repository. (Request a copy)

Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP-PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78% evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Gautschi, Oliver; Gugger, Mathias and Ratschiller, Daniel

ISSN:

0304-3835

ISBN:

17449174

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:53

Last Modified:

04 May 2014 23:15

Publisher DOI:

10.1016/j.canlet.2007.03.008

PubMed ID:

17449174

Web of Science ID:

000249141500009

URI:

https://boris.unibe.ch/id/eprint/22405 (FactScience: 34538)

Actions (login required)

Edit item Edit item
Provide Feedback